Overview

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Vifor Inc.
Vifor Pharma
Treatments:
Ferric Compounds
Criteria
Inclusion Criteria:

- Male or female, inpatient or outpatient, aged at least 18 years and not more than 60
years.

- Have a platelet count >450G/l

- Transferrin saturation (TfS) <20% or ferritin < 100µg/l

- Previously diagnosed inflammatory bowel disease (Crohn's disease or ulcerative
colitis)

- Females of child-bearing potential must have a negative urine pregnancy test at
screening and be practicing a highly effective method of birth control during the
study and for up to 1 month after the last dose of the study medication. A highly
effective method of birth control is defined as those which result in a low failure
rate (i.e. less than 1% per year) when used consistently and correctly such as
implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or
vasectomised partner. Non-childbearing potential includes being surgically sterilized
at least 6 months prior to the study or postmenopausal, defined as amenorrhoea for at
least 12 months.

- Demonstrate the ability to understand the requirements of the study, provide written
informed consent, abide by the study restrictions, and agree to undergo the required
assessments.

Exclusion Criteria:

- CDAI >220, CAI>6

- Significant anemia (hemoglobin <10.5 g/dl), or anaemia not caused by iron deficiency
(e.g. anaemia due to cancer or infection)

- Blood transfusions or iron therapy during the previous 4 weeks, or erythropoietin
treatment within the 8 weeks prior to enrollment.

- Concomitant therapy with prednisolone above 20mg/d, 6-mercaptopurine, infliximab or
azathioprine must have been initiated at least 4 months prior to study and the dose
must be stable for at least 8 weeks. Other drugs with known effects on
megakaryopoiesis (e.g. interferon-alpha).

- Severe concomitant disease or need for surgery within 8 weeks

- Hemochromatosis or other iron-storage disorders (e.g. thalassemia, siderosis, lead
poisoning anaemia, porphyria cutanea tarda)

- Treatment with an investigational drug within the 30 days prior to enrollment

- Active severe infection or malignancy other than carcinoma in situ of the cervix and
non-melanoma skin cancer.

- Bone Marrow Disease (MDS, thalassemia, etc)

- Active or chronic liver or kidney disease. Serum albumin <25 g/L or serum creatinine
>20 mg/L

- Significant cardiovascular disease, including myocardial infarction within 12 months
prior to study inclusion, congestive heart failure NYHA (New York Heart Association)
grade III or IV, or poorly controlled hypertension according to the judgment of the
investigator. Known hypersensitivity to FERINJECT®

- Positive for HIV 1/HIV 2 antibodies (anti HIV) (HIV: human immunodeficiency virus).

- Positive for hepatitis B surface-antigen (HBsAg), hepatitis C virus antibody (anti
HCV) and evidence for active hepatitis, i.e., abnormal liver function test (LFT)
results.